Background: In spite of the advances in Cancer treatment, limitations exist. Refractory cases and late presentations are particularly worrying. The uncertainty of cure and the high costs have led to the popularly of complementary and alternative medicine in cancer treatment. Herbal medicine has particular attraction because it has been shown to be working on a multi-targets direction: promoting apoptosis of cancer cells, anti-angiogenesis and immunomodulating. Research on creating a simple herbal formula with multiple effects of cancer control has started and showed in laboratory platforms promising results. Metronomic Chemotherapy: Attention on the use of old oral cytotoxic drugs in small doses for refractory and late cancer cases has started more than a decade. Satisfactory and good results have been found to be related to anti-angiogenesis, immunomodulations and cancer cell apoptosis. These findings are comparable to the use of multiple targets herbal medicine. Conclusion: Assumption is made that metronomic chemotherapy, combined with herbal medicine could be achieving synergistic effects and would be affordable to all patients.
KeywordsCancerMetronomic TreatmentHerbal Medicine
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Caner in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917.
(2014) Hong Kong Cancer Registry, “Hong Kong Cancer Statistics 2014”. Hong Kong Hospital Authority, Hong Kong. https://www3.ha.org.hk/cancereg/pdf/overview/Summary%20of%20CanStat%202014.pdf
Wang, X.S., Di, L.J., Reyes-Gibby, C.C., Guo, H., Liu, S.J. and Gleeland, C.S. (2004) End-of-Life Care in Urban Areas of China: A Survey of 60 Oncology Clinicians. Journal of Pain and Symptom Management, 27, 125-132. https://doi.org/10.1016/j.jpainsymman.2003.06.002
Chen, K., Wang, P.P., Sun, B., Li, Q., Perruccio, A., Power, D., et al. (2006) Twenty-Year Secular Changes in Sex Specific Lung Cancer Incidence Rates in an Urban Chinese Population. Lung Cancer, 51, 13-19. https://doi.org/10.1016/j.lungcan.2005.08.013
Andre, N. (2012) Metronomic Chemotherapy in Pediatric Oncology: A Way for Low-Income Countries? Metronomics Global Health Initiative. http://metronomics.newethicalbusiness.org/Metronomic-Chemotherapy-in,184
Ernst, E. and Cassileth, B.R. (1998) The Prevalence of Complementary/Alternative Medicine in Cancer: A Systematic Review. Cancer, 83, 777-782. https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4 3.0.CO;2-O
Huebner, J., Prott, F.J., Micke, O., Muecke, R., Senf, B., Dennert, G., et al. (2014) Online Survey of Cancer Patients on Complementary and Alternative Medicine. Oncology Research and Treatment, 37, 304-308. https://doi.org/10.1159/000362616
Deng, G. and Cassileth, B.R. (2005) Integrative Oncology: Complementary Therapies for Pain, Anxiety, and Mood Disturbance. CA: A Cancer Journal for Clinicians, 55, 109-116. https://doi.org/10.3322/canjclin.55.2.109
Wong, T.W., Wong, S.L. and Sturat, P.B.D. (1993) Traditional Chinese Medicine and Western Medicine in Hong Kong: A Comparison of the Consultation Processes and Side Effects. Journal of Hong Kong Medical Association, 45, 278-284.
Luo, J. and Chu, D.T. (2002) Evaluation of the Quality of Life in the Treatment of Malignant Tumor. Chinese Journal of Oncology, 24, 411-413.
Schipper, H., Clinch, J., McMurray, A. and Levitt, M. (1984) Measuring the Quality of Life of Cancer Patients: The Functional Living Index-Cancer: Development and Validation. Journal of Clinical Oncology, 2, 472-483.
Mok, T.S.K., Yeo, W., Johnson, P.J., Hui, P., Ho, W.M., Lam, K.C., et al. (2007) A Double-Blind Placebo-Controlled Randomized Study of Chinese Herbal Medicine as Complementary Therapy for Reduction of Chemotherapy-Induced Toxicity. Annals of Oncology, 18, 768-774. https://doi.org/10.1093/annonc/mdl465
Bao, Y.X., Wong, C.K., Leung, S.F., Chan, A.T., Li, P.W., Wong, E.L., et al. (2006) Clinical Studies of Immunomodulatory Activities of Yunzhi-Danshen in Patients with Nasopharyngeal Carcinoma. Journal of Alternative and Complementary Medicine, 12, 771-776. https://doi.org/10.1089/acm.2006.12.771
Wong, C.K., Bao, Y.X., Wong, E.L., Leung, P.C., Fung, K.P. and Lam, C.W. (2005) Immunomodulatory Activities of Yunzhi and Danshen in Post-Treatment Breast Cancer Patients. The American Journal of Chinese Medicine, 33, 381-395. https://doi.org/10.1142/S0192415X05002990
Wong, C.K., Tse, P.S., Wong, E.L., Leung, P.C., Fung, K.P. and Lam, C.W. (2004) Immunomodulatory Effects of Yunzhi and Danshen Capsules in Health Subjects—A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. International Immunopharmacology, 4, 201-211. https://doi.org/10.1016/j.intimp.2003.12.003
Leung, P.C., Ooi, V., Wong, E.L.Y., Au, W.C., Wong, C.K., Lam, W.K., et al. (2007) Chinese Medicine and Cancer Treatment in Hong Kong. A General Review. Asia Pacific Biotech News, 11, 1108-1112. http://www.asiabiotech.com/publication/apbn/11/english/preserved-docs/1116/1108_1113.pdf https://doi.org/10.1142/9789812709301_0003
Nikkei Medical Group (2007) Utilization Survey of Kampo Medicines. Vol. 10, 41-47.
Kono, T., Kanematsu, T. and Kitajima, M. (2009) Exodus of Kampo, Traditional Japanese Medicine, from the Complementary and Alternative Medicine: Is It Time Yet? Surgery, 146, 837-840. https://doi.org/10.1016/j.surg.2009.06.012
Zhang, Q.H. and Leung, P.C. (2015) Practice and Research on Chinese Medicine Outside of China. In: Leung, P.C. Ed., A Comprehensive Guide to Chinese Medicine, World Scientific Publisher, Singapore, 209-238. https://doi.org/10.1142/9789814667081_0008
Kummar, S., Copur, M.S., Rose, M., Wadler, S., Stephenson, J., O’Rourke, M., et al. (2011) A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-Based Chemotherapy in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 10, 85-96. https://doi.org/10.1016/j.clcc.2011.03.003
Lau, C.B.S., Yue, G.G.L., Fung, K.P., Tan, N.H. and Leung, P.C. (2015) The Potential Role of Chinese Herbal Medicines in Cancer Management. Science, 347, S45-S47.
Chung, H.L., Yue, G.G.L., To, K.F., Su, Y.L., Huang, Y. and Ko, W.H. (2007) Effect of Scutellariae Radix Extract on Experimental Dextran-Sulfate Sodium-Induced Colitis in Rats. World Journal of Gastroenterology, 13, 5605-5611.
Yue, G.G.L., Lee, J.K.M., Kowk, H.F., Cheng, L., Wong, E.C.W., Jiang, L., et al. (2015) Novel PI3K/AKT Targeting Anti-Angiogenic Activities of 4-Vinylphenol, a New Therapeutic Potential of a Well-Known Styrene Metabolite. Scientific Reports, 5, Article No. 11149. https://doi.org/10.1038/srep11149
Hibasami, H., Fujikawa, T., Takeda, H., Nishibe, S., Satoh, T., Fujisawa, T., et al. (2000) Induction of Apoptosis by Acanthopanax senticosus HARMS and Its Component, Sesamin in Human Stomach Cancer KATO III Cells. Oncology Reports, 7, 1213-1216.
Yue, G.G., Fung, K.P., Tse, G.M., Leung, P.C. and Lau, C.B. (2006) Comparative Studies of Various Ganoderma Species and Their Different Parts with Regards to Their Antitumor and Immunomodulating Activities in Vitro. Journal of Alternative and Complementary Medicine, 12, 777-789. https://doi.org/10.1089/acm.2006.12.777
Yue, G.G., Fung, K.P., Leung, P.C. and Lau, C.B. (2008) Comparative Studies on the Immunomodulatory and Antitumor Activities of the Different Parts of Fruiting Body of Ganoderma lucidum and Ganoderma Spores. Phytotherapy Research, 22, 1282-1291. https://doi.org/10.1002/ptr.2478
Han, X.Q., Yue, G.L., Yue, R.Q., Dong, C.X., Chan, C.L., Ko, C.H., et al. (2014) Structure Elucidation and Immunomodulatory Activities of a Beta Glucan from the Fruiting Bodies of Ganoderma sinense. PLoS ONE, 9, e100380. https://doi.org/10.1371/journal.pone.0100380
Yue, G.G.L., Lee, J.K.M., Li, L., Chan, K.M., Wong, E.C.W., Chan, J.Y.W., et al. (2015) Andrographis paniculata Elicits Anti-Invasion Activities by Suppressing TM4SF3 Gene Expression and by Anoikis-Sensitization in Esophageal Cancer Cells. American Journal of Cancer Research, 5, 3570-3587.
Meropol, N.J., Schrag, D., Smith, T.J., Mulvey, T.M., Langdon, R.M., Blum, D., et al. (2009) American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. Journal of Clinical Oncology, 27, 3868-3874. https://doi.org/10.1200/JCO.2009.23.1183
Hanahan, D., Bergers, G. and Bergsland, E. (2000) Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice. Journal of Clinical Investigation, 108, 1045-1047. https://doi.org/10.1172/JCI9872
Goss, P.E., Strasser-Weippl, K., Lee-Bychkovsky, B.L., Fan, L., Li, J., Chavarri-Guerra, Y., et al. (2014) Challenges to Effective Cancer Control in China, India and Russia. The Lancet Oncology, 15, 489-538. https://doi.org/10.1016/S1470-2045(14)70029-4
Andre, N., Banavali, S., Snihur, Y. and Pasquier, E. (2013) Has the Time Come for Metronomics in Low-Income and Middle-Income Countries? The Lancet Oncology, 14, e239-e248.
Kerbel, R.S. and Kamen, B.A. (2004) The Anti-Angiogenic Basic of Metronomic Chemotherapy. Nature Reviews Cancer, 4, 423-436. https://doi.org/10.1038/nrc1369
Shaked, Y., Emmenegger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y., et al. (2005) Optimal Biologic Dose of Metronomic Chemotherapy Regimens Is Associated with Maximum Anti-Angiogenic Activity. Blood, 106, 3058-3061. https://doi.org/10.1182/blood-2005-04-1422
Scharovsky, O.G., Mainetti, L.E. and Rozados, V.R. (2009) Metronomic Chemotherapy: Changing the Paradigm That More Is Better. Current Oncology, 16, 7-15. https://doi.org/10.3747/co.v16i2.420
Maiti, R. (2014) Metronomic Chemotherapy. Journal of Pharmacology and Pharmacotherapeutics, 5, 186-192. https://doi.org/10.4103/0976-500X.136098
Mross, K. and Steinbild, S. (2012) Metronomic Anti-Cancer Therapy—An Ongoing Treatment Option for Advanced Cancer Patients. Journal of Cancer Therapeutics and Research, 1, 32. https://doi.org/10.7243/2049-7962-1-32
Collova, E., Sebastiani, F., De Matteis, E., Generali, D., Aurillio, G., Boccardo, F., et al. (2011) Use of Metronomic Chemotherapy in Oncology: Results from a National Italian Survey. Tumori Journal, 97, 454-458.
Bocci, G., Tuccori, M., Emmenegger, U., Liquori, V., Falcone, A., Kerbel, R.S., et al. (2005) Cyclophosphamide-Methotrexate Metronomic Chemotherapy for the Palliative Treatment of Metastatic Breast Cancer. A Comparative Pharmacoeconomic Evaluation. Annals of Oncology, 16, 1243-1252. https://doi.org/10.1093/annonc/mdi240
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., et al. (2004) A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung. The New England Journal of Medicine, 350, 1713-1721. https://doi.org/10.1056/NEJMoa032792
Martin-Padura, I., Marighetti, P., Agliano, A., Colombo, F., Larzabal, L., Redrado, M., et al. (2012) Residual Dormant Cancer Stem-Cell Foci Are Responsible for Tumor Relapse after Antiangiogenic Metronomic Therapy in Hepatocellular Carcinoma Xenografts. Laboratory Investigation, 92, 952-966. https://doi.org/10.1038/labinvest.2012.65
Emmenegger, U., Francia, G., Shaked, Y. and Kerbel, R.S. (2010) Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer. Recent Results in Cancer Research, 180, 165-183. https://doi.org/10.1007/978-3-540-78281-0_10
Kamen, B.A. (2005) Metronomic Therapy: It Makes Sense and Is Patient Friendly. Journal of Pediatric Hematology/Oncology, 27, 571-572. https://doi.org/10.1097/01.mph.0000192148.90120.15
Sobrero, A.F., Aschele, C. and Bertino, J.R. (1997) Fluorouracil in Colorectal Cancer—A Tale of Two Drugs: Implications for Biochemical Modulation. Journal of Clinical Oncology, 15, 368-381.
Takahashi, Y., Mai, M., Sawabu, N. and Nishioka, K. (2005) A Pilot Study of Individualized Maximum Repeatable Dose (iMRD), a New Dose Finding System, of Weekly Gemcitabine for Patients with Metastatic Pancreas Cancer. Pancreas, 30, 206-210. https://doi.org/10.1097/01.mpa.0000153335.73352.c7
Pasquier, E., Kavallaris, M. and Andre, N. (2010) Metromic Chemotherapy: New Rationale for New Directions. Nature Reviews Clinical Oncology, 7, 455-465. https://doi.org/10.1038/nrclinonc.2010.82
Labrinidis, A., Hay, S., Lipis, V., Findlay, D.M. and Evdokiou, A. (2010) Zoledronic Acid Protects Against Osteosarcoma-Induced Bone Destruction but Lacks Efficacy against Pulmonary Metastases in a Syngeneic Rat Model. International Journal of Cancer, 127, 345-354. https://doi.org/10.1002/ijc.25051
Ottewell, P.D., Woodward, J.K., Lefley, D.V., Evans, C.A., Coleman, R.E. and Holen, I. (2009) Anticancer Mechanisms of Doxorubicin and Zoledronic Acid in Breast Cancer Tumor Growth in Bone. Molecular Cancer Therapeutics, 8, 2821-2832. https://doi.org/10.1158/1535-7163.MCT-09-0462
Thangapazham, R.L., Passi, N. and Maheshwari, R.K. (2007) Green Tea Polyphenol and Epigallocatechin Gallate Induce Apoptosis and Inhibit Invasion in Human Breast Cancer Cells. Cancer Biology & Therapy, 6, 1938-1943. https://doi.org/10.4161/cbt.6.12.4974
Luo, K.W., Ko, C.H., Yue, G.G., Lee, J.K., Li, K.K., Lee, M., et al. (2014) Green Tea (Camellia sinensis) Extract Inhibits Both the Metastasis and Osteolytic Components of Mammary Cancer 4T1 Lesions in Mice. The Journal of Nutritional Biochemistry, 25, 395-403. https://doi.org/10.1016/j.jnutbio.2013.11.013
Luo, K.W., Ko, C.H., Yue, G.G., Gao, S., Lee, J.K., Li, G., et al. (2015) The Combined Use of Camellia sinensis and Metronomic Zoledronic Acid in a Breast Cancer-Induced Osteolysis Mouse Model. Journal of Cancer Research and Clinical Oncology, 141, 1025-1036. https://doi.org/10.1007/s00432-014-1882-1
Luo, K.W., Yue, G.G., Ko, C.H., Lee, J.K., Gao, S., Li, L.F., et al. (2014) In Vivo and in Vitro Anti-Tumor and Anti-Metastasis Effects of Coriolus Versicolor Aqueous Extract on Mouse Mammary 4T1 Carcinoma. Phytomedicine, 21, 1078-1087. https://doi.org/10.1016/j.phymed.2014.04.020
Wong, E., Cheng, K.F. and Leung, P.C. (2012) Efficacy of Yunzhi (Trametes versicolor) on Survival in Cancer Patients: Systematic Review and Meta-Analysis. Recent Patents on Inflammation & Allergy Drug Discovery, 6, 78-87. https://doi.org/10.2174/187221312798889310
Luo, K.W., Ko, C.H., Yue, G.G., Lee, M.Y., Siu, W.S., Lee, J.K., et al. (2013) Anti-Tumor and Anti-Osteolysis Effects of the Metronomic Use of Zoledronic Acid in Primary and Metastatic Breast Cancer Mouse Models. Cancer Letters, 339, 42-48. https://doi.org/10.1016/j.canlet.2013.07.024
Zhao, X., Xu, X., Guo, L., Ragaz, J, Guo, H., Wu, J., et al. (2010) Biomarker Alterations with Metronomic Use of Low-Dose Zoledronic Acid for Breast Cancer Patients with Bone Metastases and Potential Clinical Significance. Breast Cancer Res Treat, 124, 733-743. https://doi.org/10.1007/s10549-010-1183-6
Lien, K., Georgsdottir, S., Sivanathan, L., Chan, K. and Emmenegger, U. (2013) Low-Dose Metronomic Chemotherapy: A Systematic Literature Analysis. European Journal of Cancer, 49, 3387-3395. https://doi.org/10.1016/j.ejca.2013.06.038
Noronha, V., Krishna, M.V., Patil, V., Joshi, A., Banavali, S.D. and Prabhash, K. (2013) Metronomic Therapy: Chemotherapy Revisited. Indian Journal of Cancer, 50, 142-148. https://doi.org/10.4103/0019-509X.117027